News

GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval ...
A new study highlights the Cardio-Ankle Vascular Index (CAVI) as a powerful tool for predicting COPD progression and outcomes ...
GSK’s Nucala receives US FDA approval for use in adults with chronic obstructive pulmonary disease: London, UK Saturday, May 24, 2025, 11:00 Hrs [IST] GSK plc announced that the ...
FDA approves Nucala as add-on therapy for COPD with high eosinophils, offering new hope by reducing flare-ups in patients ...
By Stephanie Brown HealthDay ReporterFRIDAY, May 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...
GSK (LSE:GSK) recently received FDA approval for Nucala for COPD treatment, potentially enhancing its market presence.
Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...
The Abu Dhabi Public Health Centre (ADPHC) and AstraZeneca FZ LLC (AstraZeneca) have signed a Memorandum of Understanding (MoU) to launch a collaborative public health project to strengthen public ...
The Abu Dhabi Public Health Centre (ADPHC) and AstraZeneca FZ LLC (AstraZeneca) have signed a Memorandum of Understanding (MoU) to launch a ...